College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou 310014, P. R. China.
Core Facility,The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou 324000, P. R. China.
Future Med Chem. 2024;16(14):1465-1484. doi: 10.1080/17568919.2024.2359893. Epub 2024 Jul 17.
Lymphoma, a blood tumor, has become the ninth most common cancer in the world in 2020. Targeted inhibition is one of the important treatments for lymphoma. At present, there are many kinds of targeted drugs for the treatment of lymphoma. Studies have shown that Histone deacetylase, Bruton's tyrosine kinase and phosphoinositide 3-kinase all play an important role in the occurrence and development of tumors and become important and promising inhibitory targets. This article mainly expounds the important role of these target protein in tumors, and introduces the mechanism of action, structure-activity relationship and clinical research of listed small molecule inhibitors of these targets, hoping to provide new ideas for the treatment of lymphoma.
淋巴瘤是一种血液肿瘤,已成为 2020 年全球第九大常见癌症。靶向抑制是淋巴瘤的重要治疗方法之一。目前,针对淋巴瘤的治疗有多种靶向药物。研究表明,组蛋白去乙酰化酶、布鲁顿酪氨酸激酶和磷酸肌醇 3-激酶在肿瘤的发生和发展中都起着重要作用,成为重要且有前途的抑制靶点。本文主要阐述了这些靶蛋白在肿瘤中的重要作用,并介绍了这些靶点的已上市小分子抑制剂的作用机制、构效关系和临床研究,希望为淋巴瘤的治疗提供新的思路。